SillaJen, Inc. Company Profile

01:39 EDT 22nd June 2018 | BioPortfolio

SillaJen, Inc., headquartered in Busan, South Korea with offices in San Francisco, California is a contract R&D company specializing in the translational and clinical development of complex biologics. The SillaJen translational research, assay, and clinical research teams offer an array of services in a quality systems environment to bring investigational products from bench to bedside. Located on the campus of Pusan National University, the company is comprised of dedicated in-house teams that collaborate closely with a network of local and USA-based world-class scientists and physicians. Born from a desire to revolutionize therapeutic approaches for patients with serious unmet medical needs and honed through years of pioneering experience guiding oncolytic vaccinia through clinical trials in Korea, the SillaJen operations are uniquely poised to assist in the development of similar cutting-edge gene and viral therapies. Additional information about SillaJen can be found at

News Articles [7 Associated News Articles listed on BioPortfolio]

SillaJen and ABL Europe Expand Collaboration

ABL will now also provide development, manufacturing, and QC release testing services for SillaJen

SillaJen to expand oncolytic virus agreement with ABL Europe

Biotherapeutics firm SillaJen expanded its manufacturing collaboration with ABL Europe, allowing ABL to develop, manufacture  -More- 

SillaJen begins Phase I/II trial of Pexa-Vec for colon cancer

South Korean firm SillaJen has started patient enrolment in a Phase I/II clinical trial of its clinical candidate pexastimogene devacirepvec...Read More... The post SillaJen begins Phase I/II trial of...

SillaJen expands oncolytic virus deal with ABL at ‘experienced’ facility in France

ABL Europe will provide development, manufacturing and quality control release testing services for SillaJenâs oncolytic virus candidate JX-970 at its facility in Strasbourg.

SillaJen initiates phase 1/2 trial of Pexa-Vec in metastatic colon cancer

SillaJen has initiated a phase 1/2 clinical trial of pexastimogene devacirepvec (Pexa-Vec) in combination with checkpoint inhibitor therapy for the treatment of metastatic colon cancer.

SillaJen, ABL expand deal to ready vaccine for clinic

Sillajen Biotherapeutics 215600 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummarySillajen Biotherapeutics SillaJen, formerly SillaJen Inc is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company's pipeline pr...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

SillaJen, Inc.

SillaJen, Inc., headquartered in Busan, South Korea with offices in San Francisco, California is a contract R&D company specializing in the translational and clinical development ...

More Information about "SillaJen, Inc." on BioPortfolio

We have published hundreds of SillaJen, Inc. news stories on BioPortfolio along with dozens of SillaJen, Inc. Clinical Trials and PubMed Articles about SillaJen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SillaJen, Inc. Companies in our database. You can also find out about relevant SillaJen, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Corporate Database Quicklinks

Searches Linking to this Company Record